Key facts
- NRG Therapeutics’s last known valuation is $51.9M (Sep 2025).
- It has raised $95.0M; the latest was Later Stage VC ($66.9M) in Sep 2025.
- Notable investors include Innovate UK, British Business Bank, M Ventures, SV Health Investors, Novartis Venture Fund — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for NRG Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for NRG Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NRG Therapeutics
Developer of a drug discovery platform intended to develop therapeutic approaches to restore mitochondrial function. The company's platform aims to make novel medicines that act through the preservation of mitochondrial function for the treatment and stopping the progression of neurodegenerative diseases, enabling physicians to treat patients with chronic disorders effectively.
- Sector
- Healthcare
- HQ
- Stevenage, United Kingdom
- Founded
- 2018
- Employees
- 7
- Website
- nrgtherapeutics.com/
- Ownership
- Privately Held (backing)
NRG Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NRG Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NRG Therapeutics in its N-PORT filings yet. We sweep new filings monthly.